This concept has been recently investigated by authors [18], reporting that, in acute coronary syndromes, the cardiovascular outcomes were strictly correlated to postprandial GLP-1 levels independently from endogenous (DPP-4 inhibitors) vs exogenous (GLP-1 agonist) treatments. The gene discussed is GLP1R; the disease is acute coronary syndrome.